CHGX News and Press, Change Finance U.S. Large Cap Fossil Fuel Free From 11/25/20

December could turn on potential vaccine approvals and the beginning of distribution. Holiday shopping also expected to be in focus as surveys disagree on spending mood. Payrolls watch is on after several months of slowing growth and recent weak data. For further details see...

As of last week, the Rydex Ratio fell to its lowest level on record. In other words, Rydex traders are now positioned more aggressively bullish than ever before, including the heady days of the dotcom mania 20 years ago. Clearly, traders have become intoxicated once again by the stren...

VIX is reaching levels in the low 20's, levels we have not seen since before the March 2020 correction. Forward VIX levels (as observed in VIX futures contracts) showed an elevated expectation for volatility at the November expiration before the 2020 election. That effect has softened...

We have recently written a couple of posts about the "exuberance" that has invaded the market since the election. Such is often seen near short- to intermediate-term peaks in markets as investors go "all-in" without a net. The markets are indeed currently exceedingly exuberant on ...

The S&P 500 is up over 11%, and the Nasdaq Composite is just past 31% this year through mid-November. While many larger-cap companies have performed well, there is one group of stocks that has been left out from this recovery: small-cap value. When the world went into quarantine, ...

The COVID-19 pandemic is the obvious main concern that is on everyone's mind both on a personal and economic basis. Everything hinges on the trajectory of potential vaccines and the measures that have to be taken until the vaccine becomes a reality both in development and distribution. ...

Last week, cyclical stocks surged as investors digested the implications of an imminent and highly effective vaccine. Which is it? Value or growth, cyclical or defensive? I'd stick with my answer from mid-August: high quality cyclicals, not deep value. From an industry standpoint,...

Recent news about the efficacy of potential COVID-19 vaccines sparked a sudden shift in equity market leadership in November. While it's too soon to say whether these trends will persist, investors should examine the balance of their equity exposures for resilience to a potential chan...

We upgrade U.S. equities to overweight, expecting this market to benefit from both structural growth trends and a potential cyclical upswing during 2021. Surging COVID cases and new restrictions in the U.S. have weighed on markets even as positive vaccine news points to an accelerated...

The world, including investors, is searching for clarity regarding future direction, but there are too many turning points that will be reached in the weeks and months ahead. There is also no guaranty as to how the initial readings of a turning point will be interpreted or whether the...